(Q44076969)

29 November 2017

Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer (English)

1 reference

29 November 2017

1 reference

Ayisha Siddiqua

1

1 reference

29 November 2017

Damodaran Chendil

2

1 reference

29 November 2017

Randall Rowland

3

1 reference

29 November 2017

Ali S Meigooni

4

1 reference

29 November 2017

Mahesh Kudrimoti

5

1 reference

29 November 2017

Mohammed Mohiuddin

6

1 reference

29 November 2017

Mansoor M Ahmed

7

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

29 November 2017

1 reference

29 November 2017

60

1 reference

29 November 2017

2

1 reference

29 November 2017

270-275

1 reference

29 November 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Radioisotopic implantation for carcinoma of the prostate: does it work better than it used to?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Perineal prostatic cancer seeding following radioactive seed brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Local tract metastasis of prostatic adenocarcinoma 8 years after (125)iodine brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Genomic sequence of human prostate specific antigen (PSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leader sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

The Clinical Usefulness of Prostate Specific Antigen: Update 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Detection of circulating prostate carcinoma cells via an enhanced reverse transcriptase-polymerase chain reaction assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Blood-based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: long term follow-up confirms the potential utility of this assay in identifying patients more likely to have biochemical recurrence (rising PSA) follo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901703-X

7 January 2021

10.1016/S0090-4295(02)01703-X

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7jm3ae4h75f4neryxkblejezb4

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_7jm3ae4h75f4neryxkblejezb4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7jm3ae4h75f4neryxkblejezb4

30 July 2022

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/7jm3ae4h75f4neryxkblejezb4

30 July 2022